pandemic has moved to almost every region around the globe ever since COVID-19 biological attack in January 2020, prompting the (WHO) to pronounce coronavirus illness a pandemic. Outperformers pursue development in all categories, including core expansion, geographical expansion, vertically and horizontally the value chain, and adjacent spaces, and according to our study,each and every industry got impacted due to this.
Because to the COVID-19 outbreak, the worldwide Tigecycline market is expected to reach USD 1730 million in 2022, with a reconfigured value of $ 4645.6 million by 2029, representing a CAGR of 17.9percent of total during the study period. Taking into account the financial consequences of the humanitarian disaster, Genuine Drug, which accounted for percent of the worldwide Tigecycline market in 2021, is forecast to reach million by 2028, rising at a revised percent CAGR in the post-COVID-19 timeframe. During this prediction period, the Hospital Pharmacies segment has been changed to a percent CAGR.
USA to be dominant market on regional basis
In 2019, the North American region is likely to continue to lead the global tigecycline market. The United States is the most important region in this continent. The key reason for this region's supremacy is widespread knowledge of Tigecycline therapy. The detrimental effects of the antibiotic tigecycline comprise lower spine agony, side pain, painful or difficult urination, vision or hearing abnormalities, coughing or hoarseness, fever or chills, and migraine. Similarly, the use of tigecycline is restricted due to a rise in mortality from ventilator- or hospital-acquired pneumonia. Further, although oral amoxicillin is more affordable than injectable tigecycline, individuals like it for treating bacterial infections. Amoxicillin 500 mg oral pill costs US$ 23.99, whilst tigecycline injectable costs US$ 79.22. The size of the market for tigecycline products globally is anticipated to be constrained by some of these factors.
Due to rising frequency, chlamydia and gonorrhoea have a significant impact in Europe. For contrast, the National Health Service's 2018 report indicates that over 44,000 men and women under the age of 25 in England received gonorrhoea diagnoses in 2017. In order to cure pathogenic infectious illnesses, pharmaceutical firms are emphasizing on releasing new products. For instance, the European Medicines Agency granted Accord Healthcare's request to sell tigecycline infusion in February 2020 for the prevention of infection skin infections. Even during projected period, these factors are anticipated to boost sales growth for tigecycline merchandise.
The worldwide Tigecycline market is predicted to increase at a CAGR of 9% from $1.5 billion in 2019 to USD 5.4 billion by 2029.
Tigecycline, also known as Tygacil, is a tetracycline antibiotic used to treat a variety of bacterial infections. Glycylcycline is an intravenous glycylcycline. Antibiotic-resistant microorganisms such as Staphylococci, Acinetobacter, and E. coli were created in response to the rising prevalence of antibiotic resistance. The structural alterations to this tetracycline derivative antibiotic have broadened its therapeutic action to cover Gram-positive and Gram-negative pathogens, including multidrug-resistant species.
it is an injectable medicine that works on a range of Gram-positive and Gram-negative bacteria, even against many that are immune to other medicines. Tigecycline was shown to be at least as effective as intravenous vancomycin and aztreonam in treating complex tissue and skin structure infections, as well as intravenous imipenem and cilastatian in treating complex intra-abdominal infections, in phase III studies.
A gram-positive bacteria has an exterior coating that renders it immune to a wide range of medications, including penicillin. The lipid bilayer of Gram-negative and Gram-positive bacteria's cell membranes distinguishes them. It's a semi-permeable wall that bacteria and other germs can't get through. The following are the most common causes of Gram-positive skin infections: Streptococcus pyogenes (group A), Enterococci, Clostridium perfringens, Streptococcus pyogenes (group B), Streptococcus pyogenes (group C), Streptococcus pyogenes (group D), Streptococcus It might also be caused by Staphylococcus aureus (which is treatable with penicillin) or other Streptoccoid bacteria.
A gram-negative Bacteria- The outer layer of Gram-negative bacteria makes them immune to several medications, including penicillin. The lipid coating of Gram-negative and Gram-positive bacteria's cell walls distinguishes them. It's a semi-permeable membrane that bacteria and other germs can't get through. The following are the common causes of Gram-negative skin infections: Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, aerogenes, Proteus mirabilis
The demand for tigecycline medicines on the market is being driven by the rising presence of gonorrhoea in the U.S. For illustration, the 2017 assessment from the Cdc and Prevention states that there would be around five-six lakhs cases of gonorrhoea diagnosed in the United States. Considering bacterial infections are becoming more common, pharmaceutical companies are concentrating on releasing treatments for treating them. As an illustration, in an effort to make Tygacil (Tigecycline) infusion more affordable, Sandoz Inc. introduced the AP-rated generic version of the medication in 2017. These elements are projected to fuel the market for tigecycline merchandise.
The analysis of several components that contribute to the industry's growth has been included in the research study. It comprises of market dynamics, restrictions, and catalysts that have a favourable or unfavourable impact on the market. This chapter also discusses many such sectors and applications that may have an impact on the market in the upcoming years. The data is made on the basis trends as well as past landmarks. This chapter also includes a breakdown of manufacturing on the worldwide market and for each category.
- Hisun Pharma
- Hansoh Pharma
- Jiagsu Aosaikang Pharmaceutical
- HICIN Pharma
- Abbott Laboratories
New innovations and developments
- The European Society of Clinical Microbiology (ESCM) and Infection suggests tigecycline as a possible rescue treatment for Clostridium difficile infections that are serious.
Tigecycline could also be utilised in susceptible people, like as those who are anemic or have cancer. Tigecycline could also be effective in the treatment of myeloid leukemia.
Tigecycline Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 5.4 billion.|
|Growth Rate||CAGR of 9% during 2021-2028|
|Segment Covered||By type, By application, Regions|
|Regions Covered||North America, Europe, Asia Pacific, South America, Middle East and South Africa|
|Key Players Profiled||Pfizer, Hisun Pharma, Hansoh Pharma, Jiagsu Aosaikang Pharmaceutical, HICIN Pharma, Abbott Laboratories & among others.|
Gram Positive Bacteria
Gram Negative Bacteria
Skin & Soft Tissue Infections
Complicated Intra-abdominal Infections
Community-acquired Bacterial Pneumonia
- Rest of Europe
- Rest of Asia Pacific
- Rest of South America
Middle East and South Africa